Karen Melissa Hallow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karen Melissa Hallow has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Gabriel Helmlinger
AstraZeneca, United States
7 shared publicationsChristine Ahlstrom
Drug Metabolism and Pharmacokinetics, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D AstraZeneca Gothenburg Sweden
5 shared publicationsDavid W. Boulton
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D AstraZeneca Gaithersburg Maryland USA
5 shared publicationsHongtao Yu
Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gaithersburg, MD, United States
5 shared publicationsPeter J. Greasley
Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), Biopharmaceuticals, R&D, AstraZeneca, Gothenburg, Sweden
5 shared publications- Hongtao Yu
Clinical Pharmacology & Quantitative Pharmacology, Clinical Pharmacology & Safety Sciences, BioPharmaceuticals R&D AstraZeneca Gaithersburg Maryland USA
4 shared publications
Latest Publications
- Open Access
- 26 November 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1332388
Kinetics of endothelin-1 and effect selective ETA antagonism on ETB activation: a mathematical modeling analysis
Introduction: Endothelin-1 (ET-1) regulates renal and vascular function, but the clinical utility of selective ETA receptor antagonists has been limited due to associated fluid retention. The mechanisms underlying fluid retention remain poorly understood but could be a consequence of changes in ET-1 binding to the unantagonized ETB receptor, either through increased ET-1 or non-selective ETB.Methods: A mathematical model of ET-1 kinetics was developed to quantify effects of ETA antagonist exposure and selectivity on concentrations of ET-1 and its complexes with ETA and ETB receptors. The model describes ET-1 production, tissue and plasma distribution, ETA and ETB receptor binding, and receptor-mediated clearance, and was calibrated and validated with human ET-1 infusion studies.Results: The model confirmed the significant role of ETB in ET-1 clearance. By varying both drug ETA selectivity (Kib/Kia) and concentration over a wide range, simulations predicted that while selective ETA antagonist (selectivity >1) always decreased [ET1-ETA], the change in [ET1-ETB] was more complex. It increased up to 45% as drug concentrations approached and exceeded Kia, but the increase was diminished as drug concentration increased further and fell below baseline at high concentrations. The drug concentration required to cause a decrease in [ET1-ETB] was lower as ETA selectivity decreased.Discussion: This is the first mechanistic mathematical model of ET-1 kinetics that describes receptor-mediated clearance, and the consequence of ETB blockade on ET-1 concentrations. It provides a useful tool that can coupled with experimental studies to quantitively understand and investigate this complex and dynamic system.
- 26 November 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1332388
Open AccessKinetics of endothelin-1 and effect selective ETA antagonism on ETB activation: a mathematical modeling analysis
Introduction: Endothelin-1 (ET-1) regulates renal and vascular function, but the clinical utility of selective ETA receptor antagonists has been limited due to associated fluid retention. The mechanisms underlying fluid retention remain poorly understood but could be a consequence of changes in ET-1 binding to the unantagonized ETB receptor, either through increased ET-1 or non-selective ETB.Methods: A mathematical model of ET-1 kinetics was developed to quantify effects of ETA antagonist exposure and selectivity on concentrations of ET-1 and its complexes with ETA and ETB receptors. The model describes ET-1 production, tissue and plasma distribution, ETA and ETB receptor binding, and receptor-mediated clearance, and was calibrated and validated with human ET-1 infusion studies.Results: The model confirmed the significant role of ETB in ET-1 clearance. By varying both drug ETA selectivity (Kib/Kia) and concentration over a wide range, simulations predicted that while selective ETA antagonist (selectivity >1) always decreased [ET1-ETA], the change in [ET1-ETB] was more complex. It increased up to 45% as drug concentrations approached and exceeded Kia, but the increase was diminished as drug concentration increased further and fell below baseline at high concentrations. The drug concentration required to cause a decrease in [ET1-ETB] was lower as ETA selectivity decreased.Discussion: This is the first mechanistic mathematical model of ET-1 kinetics that describes receptor-mediated clearance, and the consequence of ETB blockade on ET-1 concentrations. It provides a useful tool that can coupled with experimental studies to quantitively understand and investigate this complex and dynamic system.
- Open Access
- 19 August 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (22) , 4693-4707
The role of venous capacity in fluid retention with endothelin A antagonism: Mathematical modelling of the RADAR trial
Background and Purpose: Endothelin‐1 (ET‐1) receptor A (ETA) antagonists reduce proteinuria and prevent renal outcomes in chronic kidney disease (CKD) patients, but their utility has been limited because of associated fluid retention, resulting in increased heart failure risk. Understanding the mechanisms responsible for fluid retention could result in solutions that preserve renoprotective effects while mitigating fluid retention, but the complexity of the endothelin system has made identification of the underlying mechanisms challenging.Approach: We utilized a previously developed mathematical model of ET‐1 kinetics, ETA receptor antagonism, kidney function, haemodynamics, and sodium and water homeostasis to evaluate hypotheses for mechanisms of fluid retention with ETA antagonism. To do this, we simulated the RADAR clinical trial of atrasentan in patients with type 2 diabetes and CKD and evaluated the ability of the model to predict the observed decreases in haematocrit, urine albumin creatinine ratio (UACR), mean arterial pressure (MAP), and estimated glomerular filtration rate (eGFR).Background and Key Results: An effect of ETA antagonism on venodilation and increased venous capacitance was found to be the critical mechanism necessary to reproduce the simultaneous decrease in both MAP and haematocrit observed in RADAR.Conclusions and Impact: These findings indicate that fluid retention with ETA antagonism may not be caused by a direct antidiuretic effect within the kidney but is instead be an adaptive response to venodilation and increased venous capacity, which acutely tends to reduce cardiac filling pressure and cardiac output, and that fluid retention occurs in an attempt to maintain cardiac filling and cardiac output.
- 19 August 2024
- Published by Wiley in British Journal of Pharmacology
- Vol. 181 (22) , 4693-4707
Open AccessThe role of venous capacity in fluid retention with endothelin A antagonism: Mathematical modelling of the RADAR trial
Background and Purpose: Endothelin‐1 (ET‐1) receptor A (ETA) antagonists reduce proteinuria and prevent renal outcomes in chronic kidney disease (CKD) patients, but their utility has been limited because of associated fluid retention, resulting in increased heart failure risk. Understanding the mechanisms responsible for fluid retention could result in solutions that preserve renoprotective effects while mitigating fluid retention, but the complexity of the endothelin system has made identification of the underlying mechanisms challenging.Approach: We utilized a previously developed mathematical model of ET‐1 kinetics, ETA receptor antagonism, kidney function, haemodynamics, and sodium and water homeostasis to evaluate hypotheses for mechanisms of fluid retention with ETA antagonism. To do this, we simulated the RADAR clinical trial of atrasentan in patients with type 2 diabetes and CKD and evaluated the ability of the model to predict the observed decreases in haematocrit, urine albumin creatinine ratio (UACR), mean arterial pressure (MAP), and estimated glomerular filtration rate (eGFR).Background and Key Results: An effect of ETA antagonism on venodilation and increased venous capacitance was found to be the critical mechanism necessary to reproduce the simultaneous decrease in both MAP and haematocrit observed in RADAR.Conclusions and Impact: These findings indicate that fluid retention with ETA antagonism may not be caused by a direct antidiuretic effect within the kidney but is instead be an adaptive response to venodilation and increased venous capacity, which acutely tends to reduce cardiac filling pressure and cardiac output, and that fluid retention occurs in an attempt to maintain cardiac filling and cardiac output.
- Open Access
- 5 April 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1332394
Quantifying the integrated physiological effects of endothelin-1 on cardiovascular and renal function in healthy subjects: a mathematical modeling analysis
Endothelin-1 (ET-1) is a potent vasoconstrictor with strong anti-natriuretic and anti-diuretic effects. While many experimental studies have elucidated the mechanisms of ET-1 through its two receptors, ETA and ETB, the complexity of responses and sometimes conflicting data make it challenging to understand the effects of ET-1, as well as potential therapeutic antagonism of ET-1 receptors, on human physiology. In this study, we aimed to develop an integrated and quantitative description of ET-1 effects on cardiovascular and renal function in healthy humans by coupling existing experimental data with a mathematical model of ET-1 kinetics and an existing mathematical model of cardiorenal function. Using a novel agnostic and iterative approach to incorporating and testing potential mechanisms, we identified a minimal set of physiological actions of endothelin-1 through ETA and ETB receptors by fitting the physiological responses (changes in blood pressure, renal blood flow, glomerular filtration rate (GFR), and sodium/water excretion) to ET-1 infusion, with and without ETA/ETB antagonism. The identified mechanisms align with previous experimental studies on ET-1 and offer novel insights into the relative magnitude and significance of endothelin’s effects. This model serves as a foundation for further investigating the mechanisms of ET-1 and its antagonists.
- 5 April 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1332394
Open AccessQuantifying the integrated physiological effects of endothelin-1 on cardiovascular and renal function in healthy subjects: a mathematical modeling analysis
Endothelin-1 (ET-1) is a potent vasoconstrictor with strong anti-natriuretic and anti-diuretic effects. While many experimental studies have elucidated the mechanisms of ET-1 through its two receptors, ETA and ETB, the complexity of responses and sometimes conflicting data make it challenging to understand the effects of ET-1, as well as potential therapeutic antagonism of ET-1 receptors, on human physiology. In this study, we aimed to develop an integrated and quantitative description of ET-1 effects on cardiovascular and renal function in healthy humans by coupling existing experimental data with a mathematical model of ET-1 kinetics and an existing mathematical model of cardiorenal function. Using a novel agnostic and iterative approach to incorporating and testing potential mechanisms, we identified a minimal set of physiological actions of endothelin-1 through ETA and ETB receptors by fitting the physiological responses (changes in blood pressure, renal blood flow, glomerular filtration rate (GFR), and sodium/water excretion) to ET-1 infusion, with and without ETA/ETB antagonism. The identified mechanisms align with previous experimental studies on ET-1 and offer novel insights into the relative magnitude and significance of endothelin’s effects. This model serves as a foundation for further investigating the mechanisms of ET-1 and its antagonists.
- Open Access
- 13 November 2023
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 19 (11) , e1011598
Understanding heterogeneous mechanisms of heart failure with preserved ejection fraction through cardiorenal mathematical modeling
In contrast to heart failure (HF) with reduced ejection fraction (HFrEF), effective interventions for HF with preserved ejection fraction (HFpEF) have proven elusive, in part because it is a heterogeneous syndrome with incompletely understood pathophysiology. This study utilized mathematical modeling to evaluate mechanisms distinguishing HFpEF and HFrEF. HF was defined as a state of chronically elevated left ventricle end diastolic pressure (LVEDP > 20mmHg). First, using a previously developed cardiorenal model, sensitivities of LVEDP to potential contributing mechanisms of HFpEF, including increased myocardial, arterial, or venous stiffness, slowed ventricular relaxation, reduced LV contractility, hypertension, or reduced venous capacitance, were evaluated. Elevated LV stiffness was identified as the most sensitive factor. Large LV stiffness increases alone, or milder increases combined with either decreased LV contractility, increased arterial stiffness, or hypertension, could increase LVEDP into the HF range without reducing EF. We then evaluated effects of these mechanisms on mechanical signals of cardiac outward remodeling, and tested the ability to maintain stable EF (as opposed to progressive EF decline) under two remodeling assumptions: LV passive stress-driven vs. strain-driven remodeling. While elevated LV stiffness increased LVEDP and LV wall stress, it mitigated wall strain rise for a given LVEDP. This suggests that if LV strain drives outward remodeling, a stiffer myocardium will experience less strain and less outward dilatation when additional factors such as impaired contractility, hypertension, or arterial stiffening exacerbate LVEDP, allowing EF to remain normal even at high filling pressures. Thus, HFpEF heterogeneity may result from a range of different pathologic mechanisms occurring in an already stiffened myocardium. Together, these simulations further support LV stiffening as a critical mechanism contributing to elevated cardiac filling pressures; support LV passive strain as the outward dilatation signal; offer an explanation for HFpEF heterogeneity; and provide a mechanistic explanation distinguishing between HFpEF and HFrEF.
- 13 November 2023
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 19 (11) , e1011598
Open AccessUnderstanding heterogeneous mechanisms of heart failure with preserved ejection fraction through cardiorenal mathematical modeling
In contrast to heart failure (HF) with reduced ejection fraction (HFrEF), effective interventions for HF with preserved ejection fraction (HFpEF) have proven elusive, in part because it is a heterogeneous syndrome with incompletely understood pathophysiology. This study utilized mathematical modeling to evaluate mechanisms distinguishing HFpEF and HFrEF. HF was defined as a state of chronically elevated left ventricle end diastolic pressure (LVEDP > 20mmHg). First, using a previously developed cardiorenal model, sensitivities of LVEDP to potential contributing mechanisms of HFpEF, including increased myocardial, arterial, or venous stiffness, slowed ventricular relaxation, reduced LV contractility, hypertension, or reduced venous capacitance, were evaluated. Elevated LV stiffness was identified as the most sensitive factor. Large LV stiffness increases alone, or milder increases combined with either decreased LV contractility, increased arterial stiffness, or hypertension, could increase LVEDP into the HF range without reducing EF. We then evaluated effects of these mechanisms on mechanical signals of cardiac outward remodeling, and tested the ability to maintain stable EF (as opposed to progressive EF decline) under two remodeling assumptions: LV passive stress-driven vs. strain-driven remodeling. While elevated LV stiffness increased LVEDP and LV wall stress, it mitigated wall strain rise for a given LVEDP. This suggests that if LV strain drives outward remodeling, a stiffer myocardium will experience less strain and less outward dilatation when additional factors such as impaired contractility, hypertension, or arterial stiffening exacerbate LVEDP, allowing EF to remain normal even at high filling pressures. Thus, HFpEF heterogeneity may result from a range of different pathologic mechanisms occurring in an already stiffened myocardium. Together, these simulations further support LV stiffening as a critical mechanism contributing to elevated cardiac filling pressures; support LV passive strain as the outward dilatation signal; offer an explanation for HFpEF heterogeneity; and provide a mechanistic explanation distinguishing between HFpEF and HFrEF.
- Open Access
- 7 November 2023
- Published by Wiley
Predicted Dose-Response to Combination of Zibotentan with Fixed-Dose Dapagliflozin in the ZENITH Trial Population: A Mathematical Modeling Analysis
Background and Purpose: Selective endothelin A (ETA) antagonism has shown promise as a potential treatment for chronic kidney disease (CKD), but the adverse effect of fluid retention associated with ETA antagonists has limited their clinical utility. Combination of low doses of the selective ETA antagonist zibotentan with a fixed-dose sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin is currently being evaluated in the Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD) clinical trial as an approach to maximize kidney protection via ETA antagonism and SGLT2 inhibition in combination. Approach: This study utilized a quantitative systems pharmacology modeling approach to simulate the dose-response relationship of zibotentan alone and in combination with dapagliflozin in a virtual CKD patient population. Key Results: Simulations predict that interstitial fluid volume (IFV) changes will remain below baseline for zibotentan doses below 0.5 mg when combined with dapagliflozin, while the combination therapy will provide substantial additional improvements in urinary albumin-to-creatinine ratio (uACR), glomerular hypertension, and proximal tubule energy demand, indicating enhanced renoprotection. The simulation also indicate that patients with higher baseline eGFR (>30 mL/min/1.73m2) and baseline uACR (>800 mg/g) may experience greater kidney protective response to the combination therapy with less potential for detrimental fluid retention. Conclusions and impact: If the predicted results are confirmed by the ZENITH-CKD trial, this analysis will enhance mechanistic understanding of the balance between albuminuria reduction and fluid retention with this combination treatment strategy, and will provide a tool to inform optimal population selection for late phase clinical studies and lifecycle management planning.
- 7 November 2023
- Published by Wiley
Open AccessPredicted Dose-Response to Combination of Zibotentan with Fixed-Dose Dapagliflozin in the ZENITH Trial Population: A Mathematical Modeling Analysis
Background and Purpose: Selective endothelin A (ETA) antagonism has shown promise as a potential treatment for chronic kidney disease (CKD), but the adverse effect of fluid retention associated with ETA antagonists has limited their clinical utility. Combination of low doses of the selective ETA antagonist zibotentan with a fixed-dose sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin is currently being evaluated in the Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD) clinical trial as an approach to maximize kidney protection via ETA antagonism and SGLT2 inhibition in combination. Approach: This study utilized a quantitative systems pharmacology modeling approach to simulate the dose-response relationship of zibotentan alone and in combination with dapagliflozin in a virtual CKD patient population. Key Results: Simulations predict that interstitial fluid volume (IFV) changes will remain below baseline for zibotentan doses below 0.5 mg when combined with dapagliflozin, while the combination therapy will provide substantial additional improvements in urinary albumin-to-creatinine ratio (uACR), glomerular hypertension, and proximal tubule energy demand, indicating enhanced renoprotection. The simulation also indicate that patients with higher baseline eGFR (>30 mL/min/1.73m2) and baseline uACR (>800 mg/g) may experience greater kidney protective response to the combination therapy with less potential for detrimental fluid retention. Conclusions and impact: If the predicted results are confirmed by the ZENITH-CKD trial, this analysis will enhance mechanistic understanding of the balance between albuminuria reduction and fluid retention with this combination treatment strategy, and will provide a tool to inform optimal population selection for late phase clinical studies and lifecycle management planning.
- Open Access
- 6 November 2023
- Published by Wiley
The role of venous capacity in fluid retention with Endothelin A antagonism: Mathematical modeling of the RADAR trial
Background and Purpose: Endothelin-1 (ET1) receptor A (ETA) antagonists reduce proteinuria and prevent renal outcomes in patients with chronic kidney disease (CKD), but their utility has been limited because of associated fluid retention and increased heart failure risk in patients with left ventricular dysfunction. Understanding mechanisms of fluid retention could result in solutions that preserve their renoprotective effects while mitigating fluid retention, but the complexity of the endothelin system has made identification of the underlying mechanisms challenging. Approach: We utilized a previously developed mathematical model of ET-1 kinetics, ETA antagonism, kidney function, and sodium and water homeostasis to evaluate mechanistic hypotheses of fluid retention with ETA antagonism. To do this, we simulated the RADAR clinical trial of atrasentan in patients with type 2 diabetes and CKD, and evaluated the model’s ability to predict observed decreases in hematocrit, urine albumin creatinine ratio (UACR), mean arterial pressure (MAP) and estimated glomerular filtration rate (eGFR). Key Results: An effect of ETA antagonism on venodilation and increased venous capacitance was found to be the critical mechanism necessary to reproduce the simultaneous decrease in both MAP and hematocrit observed in RADAR. Conclusions and impact: These findings indicate that fluid retention with ETA antagonism may not be caused by a direct anti-diuresis effect within the kidney, but may instead be an adaptive response to venodilation and increased venous capacity, which acutely tends to reduce cardiac filling pressure and cardiac output, and that fluid retention occurs in an attempt to maintain cardiac filling and cardiac output.
- 6 November 2023
- Published by Wiley
Open AccessThe role of venous capacity in fluid retention with Endothelin A antagonism: Mathematical modeling of the RADAR trial
Background and Purpose: Endothelin-1 (ET1) receptor A (ETA) antagonists reduce proteinuria and prevent renal outcomes in patients with chronic kidney disease (CKD), but their utility has been limited because of associated fluid retention and increased heart failure risk in patients with left ventricular dysfunction. Understanding mechanisms of fluid retention could result in solutions that preserve their renoprotective effects while mitigating fluid retention, but the complexity of the endothelin system has made identification of the underlying mechanisms challenging. Approach: We utilized a previously developed mathematical model of ET-1 kinetics, ETA antagonism, kidney function, and sodium and water homeostasis to evaluate mechanistic hypotheses of fluid retention with ETA antagonism. To do this, we simulated the RADAR clinical trial of atrasentan in patients with type 2 diabetes and CKD, and evaluated the model’s ability to predict observed decreases in hematocrit, urine albumin creatinine ratio (UACR), mean arterial pressure (MAP) and estimated glomerular filtration rate (eGFR). Key Results: An effect of ETA antagonism on venodilation and increased venous capacitance was found to be the critical mechanism necessary to reproduce the simultaneous decrease in both MAP and hematocrit observed in RADAR. Conclusions and impact: These findings indicate that fluid retention with ETA antagonism may not be caused by a direct anti-diuresis effect within the kidney, but may instead be an adaptive response to venodilation and increased venous capacity, which acutely tends to reduce cardiac filling pressure and cardiac output, and that fluid retention occurs in an attempt to maintain cardiac filling and cardiac output.
- 1 July 2022
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 49 (4) , 471-486
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone
Plasma potassium regulation within a narrow range is vital for life. The risk for hyperkalemia increases when kidney function is impaired and with therapeutic interventions such as mineralocorticoid receptor antagonists (MRAs). The kidney maintains potassium homeostasis by matching potassium intake and excretion, in part through the action of aldosterone. A mechanistic mathematical model was developed and used to investigate the effect of renal impairment and MRAs on plasma potassium levels. The model describes renal potassium filtration, reabsorption, and secretion along the nephron; potassium-aldosterone regulatory feedbacks; whole body potassium balance; and the pharmacologic effects of MRAs. The model was calibrated by fitting (1) the plasma potassium and aldosterone response to potassium infusion in humans on high/low potassium diets, and (2) the acute potassium excretion response to spironolactone. The model was validated by predicting steady-state plasma potassium with sustained spironolactone treatment in hyperaldosteronism patients. The model was then used to demonstrate that (1) declining renal function alone has a small effect on plasma potassium for GFR > 30 ml/min, but an increasing effect as GFR approaches end stage renal disease (GFR ~ 15 ml/min) (2) the effect of increasing potassium intake has minimal effect at normal GFRs but increasing effect on plasma potassium as GFR declines, and 3) MRAs have a minor effect on plasma potassium when GFR is normal, but cause larger increases as GFR falls below 60 ml/min. This model provides a quantitative framework for investigating integrated impacts of diseases and therapies in this complex system.
- 1 July 2022
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 49 (4) , 471-486
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone
Plasma potassium regulation within a narrow range is vital for life. The risk for hyperkalemia increases when kidney function is impaired and with therapeutic interventions such as mineralocorticoid receptor antagonists (MRAs). The kidney maintains potassium homeostasis by matching potassium intake and excretion, in part through the action of aldosterone. A mechanistic mathematical model was developed and used to investigate the effect of renal impairment and MRAs on plasma potassium levels. The model describes renal potassium filtration, reabsorption, and secretion along the nephron; potassium-aldosterone regulatory feedbacks; whole body potassium balance; and the pharmacologic effects of MRAs. The model was calibrated by fitting (1) the plasma potassium and aldosterone response to potassium infusion in humans on high/low potassium diets, and (2) the acute potassium excretion response to spironolactone. The model was validated by predicting steady-state plasma potassium with sustained spironolactone treatment in hyperaldosteronism patients. The model was then used to demonstrate that (1) declining renal function alone has a small effect on plasma potassium for GFR > 30 ml/min, but an increasing effect as GFR approaches end stage renal disease (GFR ~ 15 ml/min) (2) the effect of increasing potassium intake has minimal effect at normal GFRs but increasing effect on plasma potassium as GFR declines, and 3) MRAs have a minor effect on plasma potassium when GFR is normal, but cause larger increases as GFR falls below 60 ml/min. This model provides a quantitative framework for investigating integrated impacts of diseases and therapies in this complex system.
- 17 October 2021
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 62 (4) , 541-554
Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis
Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) have been shown to reduce the risk of worsening heart failure (HF) in subjects with HF and a reduced ejection fraction (HFrEF) in multiple clinical trials. The DAPACARD clinical trial was conducted to examine the effects of dapagliflozin on cardiac substrate uptake, myocardial efficiency, and myocardial contractile work in subjects with type 2 diabetes mellitus. As a complement to the clinical study, a mechanistic mathematical model of cardiorenal physiology was used to quantify the influence of established natriuretic/diuretic effects of SGLT2i on cardiac function (myocardial efficiency and global longitudinal strain). Virtual participants reflecting the participant‐level characteristics in the DAPACARD trial were produced by varying model parameters over physiologically plausible ranges. A second virtual population was generated by inducing a state of HFrEF in the DAPACARD virtual participants with type 2 diabetes mellitus for comparison. Cardiac responses to placebo and SGLT2i were simulated over 42 days. Cardiac hemodynamic improvements were predicted in DAPACARD‐HFrEF virtual participants but not in DAPACARD virtual participants. In particular, the natriuresis/diuresis induced by SGLT2i improved the global longitudinal strain and myocardial efficiency in DAPACARD‐HFrEF virtual participants within the first 14 days (change from baseline: global longitudinal strain, –0.95%; and myocardial efficiency, 0.34%), whereas the global longitudinal strain and myocardial efficiency in DAPACARD virtual participants were slightly worse (change from baseline: global longitudinal strain, 0.35%; and myocardial efficiency: –0.01%). The results of the DAPACARD virtual participants modeling were in line with the clinical data but do not preclude additional effects from other mechanisms of SGLT2i.
- 17 October 2021
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 62 (4) , 541-554
Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis
Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) have been shown to reduce the risk of worsening heart failure (HF) in subjects with HF and a reduced ejection fraction (HFrEF) in multiple clinical trials. The DAPACARD clinical trial was conducted to examine the effects of dapagliflozin on cardiac substrate uptake, myocardial efficiency, and myocardial contractile work in subjects with type 2 diabetes mellitus. As a complement to the clinical study, a mechanistic mathematical model of cardiorenal physiology was used to quantify the influence of established natriuretic/diuretic effects of SGLT2i on cardiac function (myocardial efficiency and global longitudinal strain). Virtual participants reflecting the participant‐level characteristics in the DAPACARD trial were produced by varying model parameters over physiologically plausible ranges. A second virtual population was generated by inducing a state of HFrEF in the DAPACARD virtual participants with type 2 diabetes mellitus for comparison. Cardiac responses to placebo and SGLT2i were simulated over 42 days. Cardiac hemodynamic improvements were predicted in DAPACARD‐HFrEF virtual participants but not in DAPACARD virtual participants. In particular, the natriuresis/diuresis induced by SGLT2i improved the global longitudinal strain and myocardial efficiency in DAPACARD‐HFrEF virtual participants within the first 14 days (change from baseline: global longitudinal strain, –0.95%; and myocardial efficiency, 0.34%), whereas the global longitudinal strain and myocardial efficiency in DAPACARD virtual participants were slightly worse (change from baseline: global longitudinal strain, 0.35%; and myocardial efficiency: –0.01%). The results of the DAPACARD virtual participants modeling were in line with the clinical data but do not preclude additional effects from other mechanisms of SGLT2i.
- Open Access
- 16 June 2021
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 12
Cardiorenal Systems Modeling: Left Ventricular Hypertrophy and Differential Effects of Antihypertensive Therapies on Hypertrophy Regression
Cardiac and renal function are inextricably connected through both hemodynamic and neurohormonal mechanisms, and the interaction between these organ systems plays an important role in adaptive and pathophysiologic remodeling of the heart, as well as in the response to renally acting therapies. Insufficient understanding of the integrative function or dysfunction of these physiological systems has led to many examples of unexpected or incompletely understood clinical trial results. Mathematical models of heart and kidney physiology have long been used to better understand the function of these organs, but an integrated model of renal function and cardiac function and cardiac remodeling has not yet been published. Here we describe an integrated cardiorenal model that couples existing cardiac and renal models, and expands them to simulate cardiac remodeling in response to pressure and volume overload, as well as hypertrophy regression in response to angiotensin receptor blockers and beta-blockers. The model is able to reproduce different patterns of hypertrophy in response to pressure and volume overload. We show that increases in myocyte diameter are adaptive in pressure overload not only because it normalizes wall shear stress, as others have shown before, but also because it limits excess volume accumulation and further elevation of cardiac stresses by maintaining cardiac output and renal sodium and water balance. The model also reproduces the clinically observed larger LV mass reduction with angiotensin receptor blockers than with beta blockers. We further provide a mechanistic explanation for this difference by showing that heart rate lowering with beta blockers limits the reduction in peak systolic wall stress (a key signal for myocyte hypertrophy) relative to ARBs.
- 16 June 2021
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 12
Open AccessCardiorenal Systems Modeling: Left Ventricular Hypertrophy and Differential Effects of Antihypertensive Therapies on Hypertrophy Regression
Cardiac and renal function are inextricably connected through both hemodynamic and neurohormonal mechanisms, and the interaction between these organ systems plays an important role in adaptive and pathophysiologic remodeling of the heart, as well as in the response to renally acting therapies. Insufficient understanding of the integrative function or dysfunction of these physiological systems has led to many examples of unexpected or incompletely understood clinical trial results. Mathematical models of heart and kidney physiology have long been used to better understand the function of these organs, but an integrated model of renal function and cardiac function and cardiac remodeling has not yet been published. Here we describe an integrated cardiorenal model that couples existing cardiac and renal models, and expands them to simulate cardiac remodeling in response to pressure and volume overload, as well as hypertrophy regression in response to angiotensin receptor blockers and beta-blockers. The model is able to reproduce different patterns of hypertrophy in response to pressure and volume overload. We show that increases in myocyte diameter are adaptive in pressure overload not only because it normalizes wall shear stress, as others have shown before, but also because it limits excess volume accumulation and further elevation of cardiac stresses by maintaining cardiac output and renal sodium and water balance. The model also reproduces the clinically observed larger LV mass reduction with angiotensin receptor blockers than with beta blockers. We further provide a mechanistic explanation for this difference by showing that heart rate lowering with beta blockers limits the reduction in peak systolic wall stress (a key signal for myocyte hypertrophy) relative to ARBs.
- Open Access
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Mathematical Modeling of Delayed Relaxation in Heart Failure with Preserved Ejection Fraction (HF‐pEF)‐ an Effect or a Cause?
The pathophysiological mechanisms underlying heart failure with preserved ejection fraction (HF‐pEF) remain incompletely understood. One proposed hypothesis is that prolonged pressure decay of left ventricle during isovolumic relaxation, due to loss of enhancement of the ventricle, may lead to elevation of left ventricular end‐diastolic pressure (LVEDP) and a reduction in stroke volume in HF‐pEF subjects. However, while impaired relaxation is commonly observed in HF‐pEF, it is unclear whether it is a contributing cause of HF‐pEF or perhaps a consequence of other impairments. We sought to evaluate whether direct impairment in cardiac relaxation can contribute to a state of HF‐pEF using a mathematical modeling approach. We utilized an existing mathematical model of cardio‐renal hemodynamics in which a rectified sinusoidal twitch shape function drives left ventricular contraction and relaxation. To evaluate the effect of impaired relaxation, we altered the falling side of the twitch shape function so that isovolumetric relaxation time (IVRT) increased from 100 ms to 150 ms. In addition, we also evaluated the effect of delayed relaxation coupled with other ventricular changes associated with HF‐pEF, including increased ventricular stiffness. Our simulations showed that when IVRT was increased, left ventricular pressure (LV pressure) fell more slowly during diastole. However, there was minimal effect on LVEDP. Pulmonary venous pressure also fell more slowly during diastole, and the peak pulmonary venous pressure during systole was slightly increased. Ejection fraction (EF) was minimally changed. The simulated presence of hypertension, hypertrophy, and/or increased cardiac stiffness did not impact the effect of slowed relaxation. While experimental validation is needed, our simulations suggest that impaired relaxation alone may not be a primary cause for increased preload experienced by many HF‐pEF patients. It is possible that delayed relaxation is a consequence of other contributing mechanisms (e.g. impaired bioenergetics, calcium handling, or fibrosis which may impact ventricle stiffness and contractility) rather than a direct cause for elevated LV preload. While impaired relaxation had minimal effect on LVEDP, the small increases in peak pulmonary venous pressure and slower fall during diastole could impact pulmonary and atrial function in HF‐pEF.
- 14 May 2021
- Published by Wiley in The FASEB Journal
- Vol. 35 (S1)
Open AccessMathematical Modeling of Delayed Relaxation in Heart Failure with Preserved Ejection Fraction (HF‐pEF)‐ an Effect or a Cause?
The pathophysiological mechanisms underlying heart failure with preserved ejection fraction (HF‐pEF) remain incompletely understood. One proposed hypothesis is that prolonged pressure decay of left ventricle during isovolumic relaxation, due to loss of enhancement of the ventricle, may lead to elevation of left ventricular end‐diastolic pressure (LVEDP) and a reduction in stroke volume in HF‐pEF subjects. However, while impaired relaxation is commonly observed in HF‐pEF, it is unclear whether it is a contributing cause of HF‐pEF or perhaps a consequence of other impairments. We sought to evaluate whether direct impairment in cardiac relaxation can contribute to a state of HF‐pEF using a mathematical modeling approach. We utilized an existing mathematical model of cardio‐renal hemodynamics in which a rectified sinusoidal twitch shape function drives left ventricular contraction and relaxation. To evaluate the effect of impaired relaxation, we altered the falling side of the twitch shape function so that isovolumetric relaxation time (IVRT) increased from 100 ms to 150 ms. In addition, we also evaluated the effect of delayed relaxation coupled with other ventricular changes associated with HF‐pEF, including increased ventricular stiffness. Our simulations showed that when IVRT was increased, left ventricular pressure (LV pressure) fell more slowly during diastole. However, there was minimal effect on LVEDP. Pulmonary venous pressure also fell more slowly during diastole, and the peak pulmonary venous pressure during systole was slightly increased. Ejection fraction (EF) was minimally changed. The simulated presence of hypertension, hypertrophy, and/or increased cardiac stiffness did not impact the effect of slowed relaxation. While experimental validation is needed, our simulations suggest that impaired relaxation alone may not be a primary cause for increased preload experienced by many HF‐pEF patients. It is possible that delayed relaxation is a consequence of other contributing mechanisms (e.g. impaired bioenergetics, calcium handling, or fibrosis which may impact ventricle stiffness and contractility) rather than a direct cause for elevated LV preload. While impaired relaxation had minimal effect on LVEDP, the small increases in peak pulmonary venous pressure and slower fall during diastole could impact pulmonary and atrial function in HF‐pEF.